Fig 1From: Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control studyRepresentative case of a patient with EGFR (+) lung adenocarcinoma showing the change in tumor size and volume during TKI treatmentBack to article page